2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and
Management of Patients With Thoracic Aortic Disease | Circulation Science Volunteer Warning …

Abstract Background Quality indicators (QIs) are used in many healthcare settings to
measure, compare, and improve quality of care. For the efficient development of high-quality …

Background—We sought to define the factors associated with the occurrence of stroke and
systemic embolism in a large, international atrial fibrillation (AF) trial. Methods and Results …

BACKGROUND: Vitamin K antagonists have been the standard oral antithrombotic used for
more than a half century for prevention and treatment of thromboembolism. Their limitations …

Using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS),
we determined incidence, prevalence, and outcomes among hemodialysis patients with …

Background Vitamin K antagonist (VKA) therapy remains the most common method of stroke
prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited …

Objectives: This study sought to evaluate the association of air pollution with the onset of
atrial fibrillation (AF). Background: Air pollution in general and more specifically particulate …

The ACC/AHA ST-Elevation and Non–ST-Elevation Myocardial Infarction (STEMI/NSTEMI)
Performance Measures Writing Committee (the writing committee) was charged with the …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Copies: This document is available on the World Wide Web sites of the American College of
Cardiology (www. cardiosource. org) and the American Heart Association (my …